))
MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results
Manage episode 491213212 series 3381831
Content provided by MPR Weekly Dose. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MPR Weekly Dose or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; sotatercept phase 3 trial results.
247 episodes
Share
